Erratum: Cost-effectiveness of everolimus for the treatment of advanced neuroendocrine tumours of gastrointestinal or lung origin in Canada.
Sign Up to like & getrecommendations! Published in 2018 at "Current oncology"
DOI: 10.3747/co.25.4233
Abstract: [This corrects the article on p. 32 in vol. 25, PMID: 29507481.]. read more here.
Keywords: advanced neuroendocrine; everolimus treatment; treatment advanced; effectiveness everolimus ... See more keywords